ZyVersa is a clinical stage specialty biopharmaceutical company leveraging two licensed proprietary product platforms to develop pharmaceutical products that address unmet medical needs in the areas of renal and inflammatory diseases.<br /><br />Lead renal candidate, Phase 2a-ready VAR 200, mediates removal of excess intracellular lipids in the kidney’s filtration system that contribute to kidney damage leading to end-stage kidney disease.
